Lam, Lloyd T

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine

Cell death mechanisms and regulationCancer-related Molecular Pathways

Cited by 3,058

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

Lasko, L. M., Jakob, C. G., Edalji, R. P., Qiu, W., Montgomery, D., Digiammarino, E. L., Hansen, T. M., Risi, R. M., Frey, R., Manaves, V., et al. (2017) · Nature

Histone Deacetylase Inhibitors ResearchProtein Degradation and Inhibitors

Cited by 858

Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer

Faivre, E. J., McDaniel, K. F., Albert, D. H., Mantena, S. R., Plotnik, J. P., Wilcox, D., Zhang, L., Bui, M. H., Sheppard, G. S., Wang, L., et al. (2020) · Nature

Protein Degradation and InhibitorsProstate Cancer Treatment and Research

Cited by 408

Abbv-101, a Highly Potent and Selective Clinical Stage Bruton Tyrosine Kinase Degrader for the Treatment of B-Cell Malignancies

Pan, C., Gururaja, T. L., Li, H., Nguyen, H., Zhai, Y., Xie, X., Ding, R.-X., Mathew, R., Hoh, H. Y., Jia, Z. J., et al. (2023) · Blood

Protein Degradation and InhibitorsChronic Lymphocytic Leukemia Research

Cited by 10